PIL in SC seeks time-bound probe, stringent action against fake drug networks

The plea, filed by lawyer Ashwini Upadhyay, sought directions to the Centre and states to complete investigations into fake medicine cases within three months and trials within one year.

New Delhi: A PIL has been filed in the Supreme Court seeking a comprehensive national framework to curb the manufacture and sale of counterfeit and adulterated medicines, including vaccines and cough syrups.

The PIL, filed on Tuesday by lawyer Ashwini Upadhyay, made union ministries of Health and Family Welfare, Law and Justice and Women and Child Development, all states and union territories (UTs) and the Law Commission as parties.

The plea, filed through advocate-on-record Ashwani Kumar Dubey, sought directions to the Centre and states to complete investigations into fake medicine cases within three months and trials within one year.

It also calls for standard operating procedures for search, seizure and sampling, time-bound forensic examination of seized medicines, and mandatory digital recording and videography of investigative proceedings.

“There is no standard investigation procedure, time-bound trial and sentencing policy in cases of adulterated and spurious drinks and drugs. Despite the Drug and Cosmetics Act being in force since 1940, sale and manufacturing of fake medicines, syrup, injection and vaccine continue to rise. There is vacuum in the existing framework…,” the plea submitted.

It also sought a direction to the Centre and states to “mandatorily do the digital recording and videography of search, seizure, sampling and inventory proceedings”.

The plea sought directions to the Centre to frame a graded sentencing policy to ensure stringent, proportionate punishment for fake drug manufacturers and sellers.

“Direct the Law Commission of India to prepare a report suggesting the necessary changes in existing laws to prevention fake drugs,” it said.

The PIL raised concerns over alleged gaps in the enforcement of the Drugs and Cosmetics Act, 1940, saying the absence of uniform investigation procedures, dedicated mechanisms for speedy trials and effective financial investigations has hampered action against organised counterfeit medicine networks.

It referred to reported incidents involving counterfeit and adulterated medicines, including alleged fake cancer drugs supplied to hospitals in Bengaluru, seizures of counterfeit medicines and cough syrup-related deaths.

These incidents are cited by the petitioner as examples of the need for coordinated and time-bound enforcement.

It said the circulation of fake medicines poses a serious threat to public health and implicates citizens’ constitutional rights, including the right to life and health under Article 21.

  • Related Posts

    Mankind Pharma to Acquire 70% Stake in Belgium’s ACTx

    Shares of Mankind Pharma fell more than 2% on 16 October after the company announced that it has signed an agreement to acquire a 70% stake in Belgium-based biotechnology company…

    Can a drug licence be suspended before a hearing? Karnataka HC explains rule

    NEW DELHI: Can a drug licensing authority suspend a pharmaceutical distributor’s licence while issuing a show-cause notice, before considering its response? The Karnataka high court has said the procedure under…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Mankind Pharma to Acquire 70% Stake in Belgium’s ACTx

    Mankind Pharma to Acquire 70% Stake in Belgium’s ACTx

    Can a drug licence be suspended before a hearing? Karnataka HC explains rule

    Can a drug licence be suspended before a hearing? Karnataka HC explains rule

    A Boy survives 18th Floor Fall, thanks to Yashoda Medicity

    A Boy survives 18th Floor Fall, thanks to Yashoda Medicity

    AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

    AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

    FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

    FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

    Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

    Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs